Yusuke Ogitani

Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers

Ayuko Hoshino, Han Sang Kim, Linda Bojmar et al. · Cell · 2020 · 1.2K citations · Full text

Medicine, Cancer Biology, Oncology +12

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara et al. · Clinical Cancer Research · 2016 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Bystander killing effect of <scp>DS</scp>‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

Yusuke Ogitani, Katsunobu Hagihara, Masataka Oitate et al. · Cancer Science · 2016 · 715 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Toshihiko Doi, Kohei Shitara, Yoichi Naito et al. · The Lancet Oncology · 2017 · 501 citations

Medicine, Oncology, Pharmacology +17

A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model

Tomomi Nakayama Iwata, Chiaki Ishii, Saori Ishida et al. · Molecular Cancer Therapeutics · 2018 · 273 citations

Medicine, Oncology, Pharmacology +17